Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

BACKGROUND: The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Malorni, L, Curigliano, G, Minisini, A M, Cinieri, S, Tondini, C A, D’Hollander, K, Arpino, G, Bernardo, A, Martignetti, A, Criscitiello, C, Puglisi, F, Pestrin, M, Sanna, G, Moretti, E, Risi, E, Biagioni, C, McCartney, A, Boni, L, Buyse, M, Migliaccio, I, Biganzoli, L, Di Leo, A
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6454527/
https://ncbi.nlm.nih.gov/pubmed/29893790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy214
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares